THE USE OF GONADOLIBERIN AND GONADOLIBERIN AGONISTS FOR THE TREATMENT OF METABOLIC DISORDERS WHICH ARE ATTRIBUTABLE TO THE LEVEL OF PARATHYROID HORMONE BEING TOO LOW

摘要

1. Claims (for the Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE) Pharmaceutical formulation for parenteral administration for the treatment of metabolic disorders which may arise due to the secretion of endogenous parathyroid hormone being too low, which contains 0.5 to less than 5 mu g of gonadoliberin/single dose, or 0.05 to 0.5 mu g of a gonadoliberin agonist/single dose, for an adult of normal weight in a pharmaceutically acceptable vehicle. 1. Claims (for the Contracting State AT) Process for the preparation of a pharmaceutical formulation for parenteral use for the treatment of metabolic disorders which may arise due to the secretion of endogenous parathyroid hormone being too low, containing 0.5 to less than 5 mu g of gonadoliberin/single dose or 0.05 to 0.5 mu g of a gonadoliberin agonist/single dose, for an adult of normal weight, which comprises converting gonadoliberin or its analog, together with a pharmaceutically acceptable vehicle, into a suitable formulation form.